Reportedly, Amgen (AMGN) and AstraZeneca’s (AZN) experimental asthma drug tezepelumab has been granted a speedy review by the U.S. Food and Drug Administration for potential approval. The drug displayed promising results to reduce asthma attacks in patients with uncontrolled and severe forms of the respiratory condition along with the potential to use against different triggers.
“Severe asthma is a challenging, complex disease for physicians and millions of patients and has a high unmet medical need,” stated Amgen senior executive David Reese.
The companies informed that the fast-tracked review follows their application to the U.S. regulator. The decision on the drug is expected in the first quarter of next year.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.